<DOC>
	<DOC>NCT02143635</DOC>
	<brief_summary>To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with selected advanced tumors characterized by wild-type TP53.</brief_summary>
	<brief_title>Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt</brief_title>
	<detailed_description />
	<mesh_term>Li-Fraumeni Syndrome</mesh_term>
	<criteria>Patient with a TP53wt locally advanced or metastatic solid malignancy and with measurable or nonmeasurable (but evaluable) disease as determined by RECIST 1.1 criteria. Patients with the TP53wt hematological tumors (AML, ALL, HRMDS) who have failed prior therapies or who are considered inappropriate candidates for standard induction therapy. Other protocoldefined inclusion criteria may apply Prior treatment with compounds with the same mode of action Subjects with significant or uncontrolled cardiovascular disease History of thromboembolic or cerebrovascular events within the last 6 months, including transient ischemic attack, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism Previous and concomitant therapy that precludes enrollment, as defined in the protocol Known Human Immunodeficiency Virus (HIV) infection and/or active Hepatitis B or Hepatitis C infection Patients who have undergone major surgery within the 2 weeks prior to starting study treatment or who have not fully recovered from previous surgery Women of childbearing potential, unless they are using highly effective methods of contraception during dosing and for 2 weeks after study drug discontinuation Pregnant or nursing women Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HDM201,TP53wt, p53, MDM2, HDM2, advanced tumors, BLRM (Bayesian logistic regression model)</keyword>
</DOC>